Report

The viscosupplementation market is projected to grow with a CAGR of 5.8% during the forecast period (2023 - 2028).

The emergence of the COVID-19 pandemic had its impact on the viscosupplementation market due to the decline in visits to hospitals and ambulatory surgical centers because of lockdown restrictions imposed by various governments globally. Due to these restrictions, non-emergency procedures were halted in the hospitals, which have impacted the patient's life. For instance, according to a study published in the Clinical Pharmacology and Therapeutics Journal in May 2020 by Enrico Ragni et al., the presence of osteoarthritis-related concomitant disorders is expected to initiate life-threatening risks for osteoarthritis patients in the event of SARS-CoV2 viral infection. This has prompted clinicians and orthopedists to carefully check and evaluate osteoarthritis patients, not just for symptom management but also for comorbidities that may arise as a result of osteoarthritis treatment during the COVID-19 pandemic. As a result of the aforementioned factors, the market under study is projected to be impacted during the pandemic era. However, with the resumed procedures and increased hospital visits, and lessening of COVID-19 restrictions, the market is expected to gain its potential over the period.

Certain factors that are driving the market growth include the rising patient pool suffering from osteoarthritis and the increasing introduction of advanced and combination products. For instance, according to an article published by the Centers for Disease Control and Prevention in April 2020, titled "Osteoarthritis", about 32.5 million people in the United States are suffering from osteoarthritis. In addition to this, 62% of women suffer from osteoarthritis. Similarly, according to an article published by the National Center for Biotechnology Information, in January 2021, titled "Prevalence of knee osteoarthritis, its determinants, and impact on the quality of life in elderly persons in rural Ballabgarh, Haryana", it has been observed that 64.3% of the elder population is suffering from knee osteoarthritis and the elderly patients with knee osteoarthritis have considerably poorer quality-of-life. Furthermore, obesity is another risk factor contributing to orthopedic conditions. For instance, according to an article published by the National Center for Biotechnology Information, in 2021, titled "Prevalence of Obesity in India and its Neurological Implications: A Multifactor Analysis of a Nationwide Cross-Sectional Study,": the prevalence rate of obesity in India is found to be 40.3%. In addition to this, it has been that the highest rate of prevalence is found in South India with 46.51%, and the lowest in East India with 32.96%. Thus, the increasing burden of osteoarthritis in patients is likely to increase the demand for viscosupplementation procedures, which reduces the pain in joints by increasing the lubrication between them, thereby increasing the market growth over the forecast period.

However, the regulatory issues and lack of awareness regarding the viscosupplementation are likely to restrain the market expansion.

Viscosupplementation Market Trends

Single Injection Segment Expects to Register a High CAGR in the Forecast Period

The single injection segment is expected to witness significant growth over the period, owing to the factors such as providing greater physician and patient convenience, high demand for outpatient surgeries that focus on offering same-day surgical care, including preventive (surgical) and diagnostic procedures, and increasing focus of companies to develop single injection for the treatment of osteoarthritis and rising product launches.

The increasing company focuses on developing single injection products and offering treatment to patients with osteoarthritis. For instance, in October 2021, Seikagaku Corporation launched HyLink, an intra-articular single-injection viscosupplement for the treatment of knee osteoarthritis in Taiwan. In addition, in September 2020, Bioventus reached milestones with 2 million treatments worldwide with DUROLANE, its single-injection, hyaluronic acid (HA) product used in the treatment of pain associated with osteoarthritis (OA). Similarly, in August 2021, Flexion Therapeutics, Inc. announced the positive results from the randomized, open-label, Phase 2 pharmacokinetic (PK) trial of ZILRETTA (triamcinolone acetonide extended-release single injectable suspension) for the treatments of patients with shoulder osteoarthritis (OA) and adhesive capsulitis (AC) trial.

Thus, the aforementioned factors are likely to increase the demand for single injection, thereby increasing viscosupplementation market growth over the forecast period.

North America is Expected to Have the Significant Market Share

North America is expected to dominate the global viscosupplementation market over the forecast period, owing to factors such as the rising prevalence of osteoarthritis and related disorders, the rising geriatric population, well-developed healthcare infrastructure, and the increasing demand for non-surgical procedures.

The rising burden of arthritis, osteoarthritis, and knee pain is the key factor driving the demand for the viscosupplementation market in the region. For instance, according to Statistics Canada 2021, approximately 5.9 million adult Canadians had arthritis in 2020. The prevalence of arthritis increases with age and is higher among females. In addition, according to the Centers for Disease Control and Prevention (CDC) updated in October 2021, about 1 in 4 United States adults (23.7%) or about 58.5 million people have doctor-diagnosed arthritis. Similarly, according to the Government of Canada in September 2020, approximately 374,000 (1.2%) Canadians aged 16 years and older live with diagnosed rheumatoid arthritis. Thus, the demand for viscosupplementation increases with the increasing cases of arthritis and knee pain in patients, which is expected to increase the market growth over the forecast period.

In addition, with an increase in the geriatric population, there is a rise in the number of people suffering from various arthritis problems which increases the demand for non-surgical procedures thereby increasing the market growth. For instance, according to the data published by America's Health Ranking in 2021 Senior Report, in the United States, there are more than 54 million adults aged 65 and older which accounts for 16.5% of the total population and the total number of adults ages 65 and older is projected to rise to an estimated 85.7 million, accounting approximately 20% of the total population, by 2050.

Furthermore, the rising company's focus on developing viscosupplements for treating osteoarthritis and joint pain in patients is also contributing to the overall growth of the market in the region. For instance, in January 2021, Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare launched NeoVisc+ 2 mL and NeoVisc ONE 4 mL, for the treatment of pain and improvement of joint functionality in patients affected by degenerative (age-related changes) or mechanical arthropathy (related to overuse) of the knee, in Canada.

Thus, the rising burden of arthritis and related disorders, the growing geriatric population, and increasing product launches are expected to increase the market growth in this region over the forecast period.

Viscosupplementation Market Competitor Analysis

The global viscosupplementation market is competitive with the presence of major players adopting various business strategies such as partnerships, product launches, approvals, and collaboration to withhold their market position. Some of the key market players are Anika Therapeutics, Inc., Bioventus LLC, Ferring Pharmaceuticals, Fidia Farmaceutici s.p.a., Sanofi SA, Johnson & Johnson Services, Inc., Zimmer Biomet, Wellchem Pharmaceuticals Pte Ltd., and OrthogenRx Inc.

Additional Benefits:

The market estimate (ME) sheet in Excel format
3 months of analyst support